TriSalus Life Sciences, Inc. develops oncology-focused drug-delivery technology and an investigational immunotherapy program for solid tumors. Its Pressure-Enabled Drug Delivery, or PEDD, platform is used through the TriNav Infusion System in interventional radiology procedures, including TARE and TACE, for primary liver cancer and liver metastases.
Company news centers on TriNav commercial performance, clinical and preclinical data for PEDD, studies in liver tumors, research involving nelitolimod, and presentations to interventional radiology audiences. Updates also include quarterly financial results, revenue guidance, capital actions, shareholder voting matters and governance changes tied to the company’s oncology technology strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.